Mirum Pharmaceuticals reports preliminary 2025 sales of $520 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
January 12, 2026 8:30 AM EST- 2025 net product sales of approximately $520 million (preliminary and unaudited) exceed upper end of guidance
- 2026 expected global net product sales of $630 million to $650 million
- Volixibat VISTAS study in primary sclerosing cholangitis (PSC) topline data expected Q2 2026
- LIVMARLI® EXPAND study in additional cholestatic pruritus settings timing accelerated; topline data now expected Q4 2026
- Proposed acquisition of Bluejay Therapeutics to add AZURE Phase 3 studies of brelovitug in chronic hepatitis delta virus (HDV); topline data expected H2 2026
... More
